AMGN:NSD-Amgen Inc (USD)

COMMON STOCK | Drug Manufacturers - General |

Last Closing

USD 287.1

Change

+0.09 (+0.03)%

Market Cap

USD 154.96B

Volume

2.52M

Analyst Target

USD 262.76
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-06-05 )

Largest Industry Peers for Drug Manufacturers - General

Symbol Name Price(Change) Market Cap
AZN AstraZeneca PLC ADR

-0.65 (-0.89%)

USD 218.30B
SNY Sanofi ADR

+0.26 (+0.53%)

USD 126.38B
GILD Gilead Sciences Inc

+1.44 (+1.32%)

USD 122.21B
BIIB Biogen Inc

-1.50 (-1.14%)

USD 17.35B
GRFS Grifols SA ADR

+0.27 (+3.20%)

USD 6.70B
AMRN Amarin Corporation PLC

+0.01 (+0.04%)

USD 0.24B
MIRA MIRA Pharmaceuticals, Inc. Com..

-0.03 (-2.14%)

USD 0.02B
SCLX Scilex Holding Company

-0.50 (-7.17%)

N/A
SCLXW Scilex Holding Company

N/A

N/A

ETFs Containing AMGN

BBH VanEck Biotech ETF 16.13 % 0.35 %

-0.44 (0.04%)

USD 0.33B
IBB iShares Biotechnology ETF 8.22 % 0.47 %

-0.06 (0.04%)

USD 5.11B
BIS ProShares UltraShort Nasd.. 8.14 % 0.95 %

+0.02 (+0.04%)

USD 2.88M
BTEC:SW iShares Nasdaq US Biotech.. 7.89 % 0.00 %

-0.03 (0.04%)

N/A
UBIO 6.41 % 0.95 %

N/A

N/A
BIB ProShares Ultra Nasdaq Bi.. 5.99 % 0.95 %

-0.04 (0.04%)

USD 0.04B
MEDX Horizon Kinetics Medical .. 5.91 % 0.00 %

-0.05 (0.04%)

N/A
LIFE-B:CA Evolve Global Healthcare .. 5.45 % 0.00 %

+0.01 (+0.04%)

N/A
ZWHC:CA BMO Covered Call Health C.. 5.07 % 0.00 %

-0.04 (0.04%)

N/A
NDJI 4.95 % 0.00 %

N/A

N/A
LIFE-U:CA Evolve Global Healthcare .. 4.94 % 0.00 %

N/A

N/A
DOGG First Trust Exchange-Trad.. 4.75 % 0.00 %

-0.10 (0.04%)

USD 0.03B
YALL God Bless America ETF 4.70 % 0.00 %

-0.89 (0.04%)

N/A
1546:TSE NEXT FUNDS DJIA (Yen-UnHe.. 4.47 % 0.00 %

-500.00 (0.04%)

USD 19.52B
CBUF:F iShares V Public Limited .. 4.40 % 0.00 %

-0.02 (0.04%)

N/A
CSINDU:SW iShares VII PLC - iShares.. 4.39 % 0.00 %

-2.00 (0.04%)

USD 1.55B
WHCS:SW 4.21 % 0.00 %

N/A

N/A
WH2E:XETRA Invesco S&P World Health .. 3.35 % 0.00 %

-0.01 (0.04%)

N/A
FDV First Trust Capital Stren.. 3.17 % 0.00 %

-0.04 (0.04%)

N/A
IUHC:LSE iShares S&P 500 USD Healt.. 3.12 % 0.00 %

-0.01 (0.04%)

USD 2.40B
IUHC:SW iShares S&P 500 Health Ca.. 3.12 % 0.00 %

-0.10 (0.04%)

N/A
GXLV:LSE SPDR® S&P® U.S. Health .. 3.11 % 0.00 %

-11.00 (0.04%)

N/A
SXLV:SW SPDR S&P U.S. Health Care.. 3.06 % 0.00 %

N/A

N/A
HEAL:CA 2.96 % 0.00 %

N/A

N/A
XUHC:SW 2.95 % 0.00 %

N/A

N/A
NZRO 2.90 % 0.00 %

N/A

N/A
UVDV 2.35 % 0.00 %

N/A

N/A
CURE:AU Global X S&P Biotech ETF 2.32 % 0.00 %

-0.27 (0.04%)

USD 0.04B
USRI:LSE 1.80 % 0.00 %

N/A

N/A
XLVE:CA 1.72 % 0.00 %

N/A

N/A
ZDY.U:CA 1.63 % 0.33 %

N/A

N/A
HYLG 1.45 % 0.00 %

N/A

N/A
LESW:LSE 1.25 % 0.00 %

N/A

N/A
SF1CHA:SW 1.09 % 0.00 %

N/A

N/A
F1ESG:SW UBS(Lux)Fund Solutions .. 1.09 % 0.00 %

+0.01 (+0.04%)

N/A
CURE Direxion Daily Healthcare.. 0.00 % 1.06 %

-0.26 (0.04%)

USD 0.12B
DDM ProShares Ultra Dow30 0.00 % 0.95 %

-0.32 (0.04%)

N/A
DEW WisdomTree Global High Di.. 0.00 % 0.58 %

-0.07 (0.04%)

N/A
DIA SPDR Dow Jones Industrial.. 0.00 % 0.17 %

-0.97 (0.04%)

N/A
DJD Invesco Dow Jones Industr.. 0.00 % 0.09 %

-0.20 (0.04%)

N/A
FBT First Trust NYSE Arca Bio.. 0.00 % 0.57 %

-1.27 (0.04%)

N/A
FHLC Fidelity® MSCI Health Ca.. 0.00 % 0.08 %

-0.05 (0.04%)

USD 2.37B
IYH iShares U.S. Healthcare E.. 0.00 % 0.43 %

-0.04 (0.04%)

N/A
LABS 0.00 % 0.45 %

N/A

N/A
LABU Direxion Daily S&P Biotec.. 0.00 % 1.14 %

+0.10 (+0.04%)

USD 0.54B
LNGR 0.00 % 0.50 %

N/A

N/A
PBE Invesco Dynamic Biotechno.. 0.00 % 0.57 %

-0.08 (0.04%)

N/A
HONR 0.00 % 0.65 %

N/A

N/A
VSL 0.00 % 0.65 %

N/A

N/A
HHL-U:CA Harvest Healthcare Leader.. 0.00 % 0.00 %

N/A

N/A
BTEC:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

N/A

N/A
BTEK:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

-0.01 (0.04%)

N/A
BTEE:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

-0.01 (0.04%)

N/A
RXD ProShares UltraShort Heal.. 0.00 % 0.77 %

N/A

N/A
RXD ProShares UltraShort Heal.. 0.00 % 0.95 %

N/A

N/A
RXL ProShares Ultra Health Ca.. 0.00 % 0.95 %

-0.19 (0.04%)

N/A
SICK 0.00 % 0.95 %

N/A

N/A
VHT Vanguard Health Care Inde.. 0.00 % 0.10 %

-0.14 (0.04%)

N/A
XBI SPDR® S&P Biotech ETF 0.00 % 0.35 %

+0.08 (+0.04%)

N/A
XLV Health Care Select Sector.. 0.00 % 0.13 %

-0.18 (0.04%)

USD 33.98B
ZBIO Zenas BioPharma, Inc. Com.. 0.00 % 0.95 %

+0.06 (+0.04%)

N/A
ZDJ:CA BMO Dow Jones Industrial .. 0.00 % 0.26 %

+0.05 (+0.04%)

CAD 0.44B
ZWA:CA BMO Covered Call Dow Jone.. 0.00 % 0.72 %

-0.04 (0.04%)

CAD 0.20B
HHL:CA Harvest Healthcare Leader.. 0.00 % 1.15 %

-0.01 (0.04%)

N/A
DRDR:LSE iShares Healthcare Innova.. 0.00 % 0.00 %

+0.75 (+0.04%)

N/A
HEAL:LSE iShares Healthcare Innova.. 0.00 % 0.00 %

+0.02 (+0.04%)

N/A
IHCU:LSE iShares S&P 500 Health Ca.. 0.00 % 0.00 %

-2.75 (0.04%)

N/A
SXLV:LSE SPDR S&P U.S. Health Care.. 0.00 % 0.00 %

-0.05 (0.04%)

N/A
VMVL:LSE 0.00 % 0.00 %

N/A

N/A
WQDS:LSE iShares MSCI World Qualit.. 0.00 % 0.00 %

+0.75 (+0.04%)

N/A
WQDV:LSE iShares MSCI World Qualit.. 0.00 % 0.00 %

+0.01 (+0.04%)

N/A
XLDX:LSE Xtrackers LevDAX Daily Sw.. 0.00 % 0.00 %

+122.50 (+0.04%)

N/A
XSHC:LSE Xtrackers MSCI USA Health.. 0.00 % 0.00 %

-10.00 (0.04%)

USD 0.65B
XUHC:LSE Xtrackers MSCI USA Health.. 0.00 % 0.00 %

+0.10 (+0.04%)

USD 0.65B
2B70:F iShares NASDAQ US Biotech.. 0.00 % 0.00 %

N/A

USD 0.52B
EXI3:F iShares Dow Jones Industr.. 0.00 % 0.00 %

-0.55 (0.04%)

N/A
GNAR:F 0.00 % 0.00 %

N/A

N/A
MJMT:F Amundi Index Solutions - .. 0.00 % 0.00 %

+0.72 (+0.04%)

N/A
QDVG:F iShares S&P 500 Health Ca.. 0.00 % 0.00 %

N/A

N/A
QDVW:F iShares MSCI World Qualit.. 0.00 % 0.00 %

-0.02 (0.04%)

N/A
XAMB:F Amundi Index Solutions - .. 0.00 % 0.00 %

-0.24 (0.04%)

N/A
XUHC:F Xtrackers (IE) Public Lim.. 0.00 % 0.00 %

-0.20 (0.04%)

USD 0.85B
ZPDH:F SPDR S&P U.S. Health Care.. 0.00 % 0.00 %

-0.16 (0.04%)

USD 0.40B
2B70:XETRA iShares Nasdaq US Biotech.. 0.00 % 0.00 %

-0.01 (0.04%)

USD 0.52B
EXI3:XETRA iShares Dow Jones Industr.. 0.00 % 0.00 %

-0.50 (0.04%)

USD 0.30B
GNAR:XETRA 0.00 % 0.00 %

N/A

N/A
VMVL:XETRA 0.00 % 0.00 %

N/A

N/A
OUFH:XETRA 0.00 % 0.00 %

N/A

N/A
XGSD:SW Xtrackers Stoxx Global Se.. 0.00 % 0.00 %

+0.07 (+0.04%)

USD 0.68B
ESNG 0.00 % 0.00 %

N/A

N/A
HHL-B:CA Harvest Healthcare Leader.. 0.00 % 0.00 %

-0.01 (0.04%)

N/A
TDOC:CA TD Global Healthcare Lead.. 0.00 % 0.00 %

+0.02 (+0.04%)

CAD 0.08B
IBBQ Invesco Nasdaq Biotechnol.. 0.00 % 0.00 %

N/A

USD 0.04B
WELG:XETRA Amundi S&P Global Health .. 0.00 % 0.00 %

-0.03 (0.04%)

N/A
WELS:XETRA Amundi S&P Global Health .. 0.00 % 0.00 %

-0.02 (0.04%)

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - General) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 10.15% 50% F 78% C+
Dividend Return 1.83% 75% C 75% C
Total Return 11.98% 50% F 80% B-
Trailing 12 Months  
Capital Gain -6.08% 50% F 44% F
Dividend Return 3.03% 50% F 61% D-
Total Return -3.05% 50% F 45% F
Trailing 5 Years  
Capital Gain 27.22% 57% F 62% D
Dividend Return 17.85% 60% D- 60% D-
Total Return 45.07% 57% F 63% D
Average Annual (5 Year Horizon)  
Capital Gain 6.74% 80% B- 62% D
Dividend Return 9.79% 90% A- 64% D
Total Return 3.05% 60% D- 69% C-
Risk Return Profile  
Volatility (Standard Deviation) 14.78% 80% B- 84% B
Risk Adjusted Return 66.22% 90% A- 87% B+
Market Capitalization 154.96B 88% B+ 99% N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High dividend returns

The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Dividend Growth

This stock has shown below median dividend growth in the previous 5 years compared to its sector.